VolitionRX (VNRX)
Market Price (6/21/2026): $1.46 | Market Cap: $10.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
VolitionRX (VNRX)
Market Price (6/21/2026): $1.46Market Cap: $10.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 88% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -78% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns2Y Excs Rtn is -127%, 3Y Excs Rtn is -167% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -854% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 87% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 61% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -838%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -842% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -254% High stock price volatilityVol 12M is 100% Key risksVNRX key risks include [1] significant financial strain, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 88% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -78% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -127%, 3Y Excs Rtn is -167% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -854% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 87% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 61% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -838%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -842% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -254% |
| High stock price volatilityVol 12M is 100% |
| Key risksVNRX key risks include [1] significant financial strain, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/8/2026
VolitionRX (VNRX) stock has lost about 65% since 2/28/2026 because of the following key factors:
1. Poor Fiscal Q1 2026 Earnings and Guidance.
VolitionRx (VNRX) reported its fiscal Q1 2026 earnings on May 13, 2026, posting an Earnings Per Share (EPS) of -$0.97, significantly missing analysts' expectations of -$0.73 by 32.88%. Although revenue for the quarter increased to $1.0 million from $0.2 million in the comparable period of fiscal 2025, the company continued to incur an operating loss and explicitly stated that revenues remain "lumpy and difficult to predict," declining to provide fiscal year 2026 revenue guidance. This financial underperformance relative to expectations and lack of clear future revenue outlook contributed to negative investor sentiment.
2. Highly Dilutive Public Offering in June 2026.
On June 7, 2026, VolitionRx announced the pricing of a public offering of 2,960,000 common shares and warrants to purchase up to an additional 1,480,000 shares at a combined price of $1.55 per share. This offering was expected to raise approximately $4.6 million in gross proceeds before fees and expenses. The market reacted negatively to this dilutive event, with shares falling 16.8% in premarket trading on June 8, 2026, as the offering was priced at a discount, immediately diluting existing shareholders. Analysts noted that the company was "quickly burning through cash" and needed capital.
Show more
VolitionRX (VNRX) stock has lost about 65% since 2/28/2026 because of the following key factors:
1. Poor Fiscal Q1 2026 Earnings and Guidance.
VolitionRx (VNRX) reported its fiscal Q1 2026 earnings on May 13, 2026, posting an Earnings Per Share (EPS) of -$0.97, significantly missing analysts' expectations of -$0.73 by 32.88%. Although revenue for the quarter increased to $1.0 million from $0.2 million in the comparable period of fiscal 2025, the company continued to incur an operating loss and explicitly stated that revenues remain "lumpy and difficult to predict," declining to provide fiscal year 2026 revenue guidance. This financial underperformance relative to expectations and lack of clear future revenue outlook contributed to negative investor sentiment.
2. Highly Dilutive Public Offering in June 2026.
On June 7, 2026, VolitionRx announced the pricing of a public offering of 2,960,000 common shares and warrants to purchase up to an additional 1,480,000 shares at a combined price of $1.55 per share. This offering was expected to raise approximately $4.6 million in gross proceeds before fees and expenses. The market reacted negatively to this dilutive event, with shares falling 16.8% in premarket trading on June 8, 2026, as the offering was priced at a discount, immediately diluting existing shareholders. Analysts noted that the company was "quickly burning through cash" and needed capital.
Show more
Updated on 6/8/2026
VolitionRX (VNRX) stock has lost about 65% since 2/28/2026 because of the following key factors:
1. Poor Fiscal Q1 2026 Earnings and Guidance.
VolitionRx (VNRX) reported its fiscal Q1 2026 earnings on May 13, 2026, posting an Earnings Per Share (EPS) of -$0.97, significantly missing analysts' expectations of -$0.73 by 32.88%. Although revenue for the quarter increased to $1.0 million from $0.2 million in the comparable period of fiscal 2025, the company continued to incur an operating loss and explicitly stated that revenues remain "lumpy and difficult to predict," declining to provide fiscal year 2026 revenue guidance. This financial underperformance relative to expectations and lack of clear future revenue outlook contributed to negative investor sentiment.
2. Highly Dilutive Public Offering in June 2026.
On June 7, 2026, VolitionRx announced the pricing of a public offering of 2,960,000 common shares and warrants to purchase up to an additional 1,480,000 shares at a combined price of $1.55 per share. This offering was expected to raise approximately $4.6 million in gross proceeds before fees and expenses. The market reacted negatively to this dilutive event, with shares falling 16.8% in premarket trading on June 8, 2026, as the offering was priced at a discount, immediately diluting existing shareholders. Analysts noted that the company was "quickly burning through cash" and needed capital.
3. Negative Perception from Reverse Stock Split in April 2026.
A one-for-twenty (1-for-20) reverse stock split for VNRX became effective on April 28, 2026, following stockholder approval on March 31, 2026. Reverse stock splits are often viewed as a negative signal by the market, indicating that a company is struggling to maintain its share price and meet listing requirements rather than demonstrating fundamental growth. Although it allowed the company to meet NYSE American compliance, it did not address underlying financial challenges and often precedes further stock price depreciation.
4. Persistent High Cash Burn and Reliance on Dilutive Financing.
VolitionRx continued to demonstrate a high cash burn rate, with net cash used in operating activities totaling $5.3 million in fiscal Q1 2026. The company has consistently relied on external financing to fund operations, including $5.4 million from equity sales through an at-the-market facility and $1.9 million from the issuance of a convertible note in Q1 2026. In January 2026, the company also secured almost $2 million through a Senior Secured Convertible Promissory Note. The ongoing need for capital, largely met through dilutive offerings, underscores financial instability and pressures the stock's valuation, as the company's ability to continue as a going concern is dependent on successful commercialization and continued financing.
Show less
VolitionRX (VNRX) stock has lost about 65% since 2/28/2026 because of the following key factors:
1. Poor Fiscal Q1 2026 Earnings and Guidance.
VolitionRx (VNRX) reported its fiscal Q1 2026 earnings on May 13, 2026, posting an Earnings Per Share (EPS) of -$0.97, significantly missing analysts' expectations of -$0.73 by 32.88%. Although revenue for the quarter increased to $1.0 million from $0.2 million in the comparable period of fiscal 2025, the company continued to incur an operating loss and explicitly stated that revenues remain "lumpy and difficult to predict," declining to provide fiscal year 2026 revenue guidance. This financial underperformance relative to expectations and lack of clear future revenue outlook contributed to negative investor sentiment.
2. Highly Dilutive Public Offering in June 2026.
On June 7, 2026, VolitionRx announced the pricing of a public offering of 2,960,000 common shares and warrants to purchase up to an additional 1,480,000 shares at a combined price of $1.55 per share. This offering was expected to raise approximately $4.6 million in gross proceeds before fees and expenses. The market reacted negatively to this dilutive event, with shares falling 16.8% in premarket trading on June 8, 2026, as the offering was priced at a discount, immediately diluting existing shareholders. Analysts noted that the company was "quickly burning through cash" and needed capital.
3. Negative Perception from Reverse Stock Split in April 2026.
A one-for-twenty (1-for-20) reverse stock split for VNRX became effective on April 28, 2026, following stockholder approval on March 31, 2026. Reverse stock splits are often viewed as a negative signal by the market, indicating that a company is struggling to maintain its share price and meet listing requirements rather than demonstrating fundamental growth. Although it allowed the company to meet NYSE American compliance, it did not address underlying financial challenges and often precedes further stock price depreciation.
4. Persistent High Cash Burn and Reliance on Dilutive Financing.
VolitionRx continued to demonstrate a high cash burn rate, with net cash used in operating activities totaling $5.3 million in fiscal Q1 2026. The company has consistently relied on external financing to fund operations, including $5.4 million from equity sales through an at-the-market facility and $1.9 million from the issuance of a convertible note in Q1 2026. In January 2026, the company also secured almost $2 million through a Senior Secured Convertible Promissory Note. The ongoing need for capital, largely met through dilutive offerings, underscores financial instability and pressures the stock's valuation, as the company's ability to continue as a going concern is dependent on successful commercialization and continued financing.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -66.4% change in VNRX stock from 2/28/2026 to 6/20/2026 was primarily driven by a -74.5% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.26 | 1.43 | -66.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 67.5% |
| P/S Multiple | 15.7 | 4.0 | -74.5% |
| Shares Outstanding (Mil) | 5 | 7 | -21.4% |
| Cumulative Contribution | -66.4% |
Market Drivers
2/28/2026 to 6/20/2026| Return | Correlation | |
|---|---|---|
| VNRX | -66.4% | |
| Market (SPY) | 9.2% | 23.3% |
| Sector (XLV) | -6.4% | 25.2% |
Fundamental Drivers
The -77.8% change in VNRX stock from 11/30/2025 to 6/20/2026 was primarily driven by a -83.1% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.43 | 1.43 | -77.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 67.5% |
| P/S Multiple | 23.6 | 4.0 | -83.1% |
| Shares Outstanding (Mil) | 5 | 7 | -21.4% |
| Cumulative Contribution | -77.8% |
Market Drivers
11/30/2025 to 6/20/2026| Return | Correlation | |
|---|---|---|
| VNRX | -77.8% | |
| Market (SPY) | 9.9% | 10.7% |
| Sector (XLV) | -4.4% | 4.2% |
Fundamental Drivers
The -85.8% change in VNRX stock from 5/31/2025 to 6/20/2026 was primarily driven by a -89.2% change in the company's P/S Multiple.| (LTM values as of) | 5312025 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.06 | 1.43 | -85.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 88.5% |
| P/S Multiple | 37.1 | 4.0 | -89.2% |
| Shares Outstanding (Mil) | 5 | 7 | -29.9% |
| Cumulative Contribution | -85.8% |
Market Drivers
5/31/2025 to 6/20/2026| Return | Correlation | |
|---|---|---|
| VNRX | -85.8% | |
| Market (SPY) | 28.1% | 11.1% |
| Sector (XLV) | 14.6% | 6.3% |
Fundamental Drivers
The -95.4% change in VNRX stock from 5/31/2023 to 6/20/2026 was primarily driven by a -98.5% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6202026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.00 | 1.43 | -95.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 2 | 621.1% |
| P/S Multiple | 272.7 | 4.0 | -98.5% |
| Shares Outstanding (Mil) | 3 | 7 | -56.3% |
| Cumulative Contribution | -95.4% |
Market Drivers
5/31/2023 to 6/20/2026| Return | Correlation | |
|---|---|---|
| VNRX | -95.4% | |
| Market (SPY) | 85.7% | 7.4% |
| Sector (XLV) | 22.9% | 8.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VNRX Return | -19% | -23% | -70% | -16% | -57% | -73% | -98% |
| Peers Return | -20% | -61% | 37% | 43% | 127% | 1% | 39% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| VNRX Win Rate | 33% | 42% | 17% | 42% | 33% | 33% | |
| Peers Win Rate | 48% | 27% | 54% | 50% | 57% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| VNRX Max Drawdown | -54% | -58% | -79% | -58% | -74% | -81% | |
| Peers Max Drawdown | -48% | -73% | -40% | -30% | -48% | -41% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GH, GRAL, NTRA, VCYT, NEO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | VNRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -28.7% | -18.8% |
| % Gain to Breakeven | 40.3% | 23.1% |
| Time to Breakeven | 24 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.5% | -7.8% |
| % Gain to Breakeven | 25.8% | 8.5% |
| Time to Breakeven | 8 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.8% | -33.7% |
| % Gain to Breakeven | 95.1% | 50.9% |
| Time to Breakeven | 315 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -41.0% | -19.2% |
| % Gain to Breakeven | 69.4% | 23.8% |
| Time to Breakeven | 47 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -43.0% | -3.7% |
| % Gain to Breakeven | 75.3% | 3.9% |
| Time to Breakeven | 828 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -50.9% | -0.2% |
| % Gain to Breakeven | 103.8% | 0.2% |
| Time to Breakeven | 45 days | 1 days |
In The Past
VolitionRX's stock fell -28.7% during the 2025 US Tariff Shock. Such a loss loss requires a 40.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | VNRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -28.7% | -18.8% |
| % Gain to Breakeven | 40.3% | 23.1% |
| Time to Breakeven | 24 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -20.5% | -7.8% |
| % Gain to Breakeven | 25.8% | 8.5% |
| Time to Breakeven | 8 days | 18 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.8% | -33.7% |
| % Gain to Breakeven | 95.1% | 50.9% |
| Time to Breakeven | 315 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -41.0% | -19.2% |
| % Gain to Breakeven | 69.4% | 23.8% |
| Time to Breakeven | 47 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -43.0% | -3.7% |
| % Gain to Breakeven | 75.3% | 3.9% |
| Time to Breakeven | 828 days | 6 days |
| 2013 Taper Tantrum | ||
| % Loss | -50.9% | -0.2% |
| % Gain to Breakeven | 103.8% | 0.2% |
| Time to Breakeven | 45 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -33.3% | -17.9% |
| % Gain to Breakeven | 50.0% | 21.8% |
| Time to Breakeven | 1 days | 123 days |
In The Past
VolitionRX's stock fell -28.7% during the 2025 US Tariff Shock. Such a loss loss requires a 40.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About VolitionRX (VNRX)
VolitionRx Limited (VNRX) is a multi-national epigenetics company dedicated to developing innovative blood tests for the diagnosis of various cancers and other diseases worldwide. The company utilizes its proprietary Nucleosomics technology platform to create these advanced diagnostic solutions, aiming to provide earlier and more accessible detection methods.
The core of VolitionRx's offerings revolves around its Nu.Q product family. This includes Nu.Q tests for human cancer detection, Nu.Q Nets for monitoring the immune system, and Nu.Q Vet, a specific cancer screening test tailored for veterinary applications. Additionally, VolitionRx provides Nu.Q Capture, a solution designed to capture and concentrate samples for more accurate diagnosis, and Nu.Q Discover, which is used for profiling nucleosomes, primarily serving research and development purposes.
Based in Austin, Texas, VolitionRx primarily serves markets in human healthcare, veterinary medicine, and scientific research. Its customers include healthcare providers, veterinary professionals, and research institutions globally who are seeking non-invasive, blood-based diagnostic and monitoring tools to improve outcomes across a wide spectrum of diseases.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe VolitionRX:
- The Exact Sciences (EXAS) of blood-based cancer screening.
- The Guardant Health (GH) of epigenetic cancer blood tests.
AI Analysis | Feedback
- Nu.Q: Blood tests developed to detect various cancers.
- Nu.Q Nets: Tests used for monitoring the immune system.
- Nu.Q Vet cancer screening test: A specific cancer screening test for veterinary applications.
- Nu.Q Capture: A technology designed for capturing and concentrating samples to enhance diagnostic accuracy.
- Nu.Q Discover: A solution dedicated to profiling nucleosomes.
- Nucleosomics: The core technology platform underpinning the company's blood test development.
AI Analysis | Feedback
VolitionRX (VNRX) primarily sells its products and solutions to other companies and institutions rather than directly to individuals. Based on public information, its major customers and partners include:
- Heska Corporation (HSKA): Heska Corporation is a global provider of advanced veterinary diagnostic and specialty products. They have a commercialization agreement with VolitionRX for the Nu.Q Vet cancer screening test in the United States and Europe, making them a key customer and distribution partner for VolitionRX's veterinary product line.
- Active Motif: Active Motif is a leading provider of innovative tools for epigenetics and gene regulation research. They hold an exclusive license agreement with VolitionRX for the Nu.Q Discover solution in the research market, utilizing VolitionRX's technology for profiling nucleosomes.
- Diagnostic Laboratories and Research Institutions: VolitionRX's other products, such as Nu.Q for cancer detection, Nu.Q Nets for immune system monitoring, and Nu.Q Capture for sample concentration, are developed for use by diagnostic laboratories, hospitals, clinics, and academic and pharmaceutical research institutions worldwide. While not single named entities, these categories represent critical customer segments that integrate VolitionRX's tests into their diagnostic services or utilize them for research and development.
AI Analysis | Feedback
null
AI Analysis | Feedback
```html
Cameron Reynolds, President & Group Chief Executive Officer
An experienced entrepreneurial executive with expertise in biotechnology companies, Cameron Reynolds founded VolitionRx in 2010. He has extensive experience in the management, structuring, and strategic planning of start-up companies, having held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of various public and private enterprises. Prior to VolitionRx, he held roles at companies such as KAL Energy, Inc., ProBio, Inc., Wellfully Ltd., and several mining and resources companies.
Terig Hughes, Group Chief Financial Officer
Terig Hughes is a seasoned finance professional with over twenty-five years of accounting, finance, and business management experience gained internationally. He joined VolitionRx from AUM Biosciences Pte. Ltd., where he served as Chief Financial Officer since 2018. Before AUM Biosciences, Mr. Hughes held several senior leadership positions at Elsevier, a division of RELX Group plc, including regional Managing Director and regional Finance Director for Elsevier Health Solutions. His expertise includes financial reporting, planning & analysis, profit and loss management, product commercialization, licensing, and distributor management.
Gaetan Michel, Chief Operating Officer
Dr. Gaetan Michel has been with Volition for almost seven years, previously serving as Chief Operating Officer of Belgian Volition and currently as Chief Executive Officer of Belgian Volition, in addition to his role as Chief Operating Officer for VolitionRx Ltd. He brings over 15 years of project management, manufacturing, and operational experience from companies such as AAT (Advanced Array Technology), EAT (Eppendorf Array Technology), and KitoZyme. He also served as CEO of Volition Veterinary Diagnostics Development LLC from 2020-2021 and as Production Director at Bone Therapeutics SA.
Jasmine Kway, Chief Executive Officer, Singapore Volition
Dr. Jasmine Kway possesses a proven track record in achieving positive business results through developing strategic business alliances, identifying new markets, and developing business processes. She has worked with numerous health and regulatory bodies across Asia, successfully commercializing technologies and expanding companies into Asian markets. Before joining Volition, Dr. Kway was the Chief Executive Officer of IP practice at RHT i-Assets Advisory and Executive Vice President, Business Development at Transpacific IP Group Limited. She is recognized as a leading intellectual property strategist.
Gael Forterre, Chief Commercial Officer
Mr. Gael Forterre has over 15 years of experience investing in and scaling fast-growing companies. He began his career as a hedge fund analyst in Paris and later launched Armori Capital Management LLC in 2014, where he managed numerous investments and supported portfolio companies. Most recently, from 2017 until joining Volition, he served as the Chief Executive Officer of Ucroo Incorporated, leading the company to significant revenue growth. He continues to serve on the board of Ucroo Incorporated and Article22. ```
An experienced entrepreneurial executive with expertise in biotechnology companies, Cameron Reynolds founded VolitionRx in 2010. He has extensive experience in the management, structuring, and strategic planning of start-up companies, having held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of various public and private enterprises. Prior to VolitionRx, he held roles at companies such as KAL Energy, Inc., ProBio, Inc., Wellfully Ltd., and several mining and resources companies.
Terig Hughes, Group Chief Financial Officer
Terig Hughes is a seasoned finance professional with over twenty-five years of accounting, finance, and business management experience gained internationally. He joined VolitionRx from AUM Biosciences Pte. Ltd., where he served as Chief Financial Officer since 2018. Before AUM Biosciences, Mr. Hughes held several senior leadership positions at Elsevier, a division of RELX Group plc, including regional Managing Director and regional Finance Director for Elsevier Health Solutions. His expertise includes financial reporting, planning & analysis, profit and loss management, product commercialization, licensing, and distributor management.
Gaetan Michel, Chief Operating Officer
Dr. Gaetan Michel has been with Volition for almost seven years, previously serving as Chief Operating Officer of Belgian Volition and currently as Chief Executive Officer of Belgian Volition, in addition to his role as Chief Operating Officer for VolitionRx Ltd. He brings over 15 years of project management, manufacturing, and operational experience from companies such as AAT (Advanced Array Technology), EAT (Eppendorf Array Technology), and KitoZyme. He also served as CEO of Volition Veterinary Diagnostics Development LLC from 2020-2021 and as Production Director at Bone Therapeutics SA.
Jasmine Kway, Chief Executive Officer, Singapore Volition
Dr. Jasmine Kway possesses a proven track record in achieving positive business results through developing strategic business alliances, identifying new markets, and developing business processes. She has worked with numerous health and regulatory bodies across Asia, successfully commercializing technologies and expanding companies into Asian markets. Before joining Volition, Dr. Kway was the Chief Executive Officer of IP practice at RHT i-Assets Advisory and Executive Vice President, Business Development at Transpacific IP Group Limited. She is recognized as a leading intellectual property strategist.
Gael Forterre, Chief Commercial Officer
Mr. Gael Forterre has over 15 years of experience investing in and scaling fast-growing companies. He began his career as a hedge fund analyst in Paris and later launched Armori Capital Management LLC in 2014, where he managed numerous investments and supported portfolio companies. Most recently, from 2017 until joining Volition, he served as the Chief Executive Officer of Ucroo Incorporated, leading the company to significant revenue growth. He continues to serve on the board of Ucroo Incorporated and Article22. ```
AI Analysis | Feedback
The key risks to VolitionRX (VNRX) are primarily centered around regulatory hurdles, the successful development and commercialization of its diagnostic tests, and intense market competition.
- Regulatory Approval and Market Acceptance Challenges: VolitionRX's ability to generate revenue and successfully execute its business plan heavily depends on obtaining the necessary regulatory clearances and approvals to distribute and market its diagnostic products, particularly for its various Nu.Q tests. Even with approvals, there is a significant risk that the marketplace, including healthcare providers and patients, may not accept its products.
- Clinical Trial Success and Product Efficacy: The successful development and commercialization of VolitionRX's diagnostic and disease monitoring products are contingent upon favorable outcomes from ongoing and future clinical trials. Risks include the failure to achieve desired efficacy results in studies testing its tests, delays in clinical development, or inconclusive data, which could impede regulatory approval and market adoption.
- Intense Competition and Rapid Technological Obsolescence: The diagnostics and disease monitoring market, particularly in epigenetics and cancer detection, is highly competitive and characterized by rapid technological advancements. VolitionRX faces the risk that its current and pipeline products may become obsolete due to the emergence of superior or more cost-effective technologies from competitors, or that intense competition will limit its market share and profitability.
AI Analysis | Feedback
null
AI Analysis | Feedback
VolitionRx Limited (VNRX), an epigenetics company specializing in blood tests for various diseases, operates in several significant addressable markets for its key products and technologies:
-
Nu.Q (Cancer Detection / Nucleosomics Technology Platform):
- VolitionRx's Capture-Seq™ Platform, which contributes to cancer detection, represents an annualized global market opportunity of approximately $23 billion.
- The broader global liquid biopsy market, which includes technologies like VolitionRx's, was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. Another estimate places the global liquid biopsy market at USD 4.8 billion in 2024, expanding to USD 20.7 billion by 2034 with a CAGR of 15.8% from 2025–2034. North America held the largest share of the liquid biopsy market, accounting for 50.99% in 2025.
- The global oncology blood testing market is projected to grow from USD 5.9 billion in 2025 to USD 24.2 billion by 2035, at a compound annual growth rate (CAGR) of 15.2%. North America is expected to dominate this market, holding a 52.6% share in 2025.
- For blood cancer diagnostics, a specific application for Nu.Q, the global market was estimated at USD 10.83 billion in 2024 and is projected to reach USD 16.04 billion by 2030, with a CAGR of 6.87% from 2025 to 2030. North America held the largest share of the blood cancer diagnostics market, accounting for 37.7% in 2024.
- The global multi-cancer early detection (MCED) test market, where liquid biopsy plays a significant role, was valued at USD 1.5 billion in 2024 and is expected to grow from USD 1.8 billion in 2025 to USD 5.8 billion in 2034, at a CAGR of 14.1%. The U.S. MCED test market reached USD 621.1 million in 2024.
-
Nu.Q Nets (Monitoring the Immune System / NETosis-associated diseases):
- VolitionRx identifies a Total Addressable Market of $3.8 billion for diseases associated with NETosis. This market opportunity applies to the 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway), and the U.K., where the Nu.Q® NETs assay is CE-Marked and commercially available.
-
Nu.Q Vet (Veterinary Cancer Screening):
- For canine cancer screening, VolitionRx cited a Total Addressable Market of approximately $100 million for the U.S., Europe, and Japan, expanding to just under $150 million with the inclusion of China.
- For feline cancer, specifically feline lymphoma, VolitionRx notes that over 18 million senior cats (aged 8+) in the U.S. represent a recurring annual screening opportunity. The company believes a feline equivalent could potentially double its total addressable market in the companion animal space.
- The broader global veterinary oncology diagnostics market was estimated at USD 2.17 billion in 2024 and is projected to grow at a CAGR of 8.4% from 2025 to 2030. Another report estimates the global market at USD 3.15 billion in 2025, projected to reach around USD 7.25 billion by 2035, with a CAGR of 8.7% from 2026 to 2035. North America held the largest share of the market, at 53.9% in 2024. The U.S. veterinary oncology diagnostics market size was estimated at USD 980.16 million in 2023 and is expected to reach USD 2114.83 million by 2033.
AI Analysis | Feedback
VolitionRX (VNRX) is poised for future revenue growth over the next 2-3 years, driven by several key commercialization strategies and product expansions.
- Accelerated Sales and Expansion of Nu.Q Vet Cancer Test: VolitionRX anticipates significant revenue acceleration from its Nu.Q Vet cancer test. This growth is expected to stem from recent product launches and expanded distribution networks, including partnerships with major distributors like Antech Diagnostics (part of Mars Pet Care Group) in the U.S. and Europe, and Fujifilm Vet Systems in Japan. Additionally, the introduction of a feline equivalent of the Nu.Q Vet test is expected to broaden its market reach within the companion animal sector.
- Monetization of Nu.Q NETs and Capture-PCR™ through Licensing Agreements: The company is focused on monetizing its intellectual property for Nu.Q NETs and Capture-PCR™ technologies through licensing agreements in the human diagnostics space. VolitionRX expects substantial clinical data for these technologies to be completed, potentially leading to ongoing royalties and meaningful milestone payments within the next 12 months. Discussions with leading diagnostic and liquid biopsy companies are ongoing, with additional agreements expected to be announced throughout 2026. The recently submitted Capture-Seq™ platform, for instance, represents a multi-billion dollar opportunity in cancer detection.
- Growth and Partnerships for Nu.Q Discover Services: Nu.Q Discover has shown substantial revenue growth, with a strong pipeline of opportunities exceeding $1 million. A co-marketing agreement with Hologic Diagenode is projected to further accelerate the expansion of these services to a broader customer base, including top pharmaceutical and diagnostic companies globally.
- Commercialization of Nu.Q Cancer Assays in Human Diagnostics: VolitionRX achieved a significant milestone with the first sale of its Nu.Q Cancer assays to Hospices Civils de Lyon in France, marking a step towards routine clinical use in cancer management. A reimbursement submission in France is underway, with routine clinical use for lung cancer expected by the fourth quarter of 2026, which is considered a major driver for commercialization and licensing in the human cancer field.
- Receipt of Milestone Payments from Existing and Future Licensing Deals: The company has a history of receiving milestone payments from licensing agreements, such as the $23 million from its deal with Heska (now Antech) for Nu.Q Vet, which is expected to continue earning out in 2024. VolitionRX's overarching commercialization strategy relies on securing further licensing agreements, anticipating upfront payments, milestone payments, and future recurring revenue streams across its various diagnostic platforms.
AI Analysis | Feedback
Share Issuance
- In March and January 2026, VolitionRx issued shares to Lind Global Asset Management XII LLC to satisfy payment obligations under a senior secured convertible promissory note, including 1,956,178 shares for a $416,666 payment in February 2026, and a total of 4,463,689 shares for $1,000,000 in January 2026.
- In October 2025, the company priced an underwritten public offering of 11,550,000 shares of common stock and warrants, expecting to generate approximately $6.0 million in gross proceeds.
- In March 2025, VolitionRx issued 2,363,636 shares in a registered direct offering, resulting in net proceeds of over $2.3 million.
Inbound Investments
- In January 2026, VolitionRx secured $2.0 million in gross proceeds from Lind Global Asset Management XII LLC through an amended securities purchase agreement, which included the issuance of a senior secured convertible promissory note and common stock purchase warrants. This was an addition to a previous $7.5 million senior secured convertible promissory note and warrants from May 2025 with the same investor.
- On September 30, 2024, Armistice Capital, LLC acquired 9,223,380 shares of VolitionRX Ltd for approximately $5.54 million, establishing a significant new holding in its portfolio.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| VolitionRX Earnings Notes | 12/16/2025 | |
| Would You Still Hold VolitionRX Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 58.69 |
| Mkt Cap | 3.4 |
| Rev LTM | 644 |
| Op Inc LTM | -201 |
| FCF LTM | -13 |
| FCF 3Y Avg | -23 |
| CFO LTM | 1 |
| CFO 3Y Avg | -8 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 28.0% |
| Rev Chg 3Y Avg | 31.0% |
| Rev Chg Q | 33.5% |
| QoQ Delta Rev Chg LTM | 7.3% |
| Op Inc Chg LTM | 9.9% |
| Op Inc Chg 3Y Avg | 11.0% |
| Op Mgn LTM | -27.2% |
| Op Mgn 3Y Avg | -40.8% |
| QoQ Delta Op Mgn LTM | 3.0% |
| CFO/Rev LTM | -7.2% |
| CFO/Rev 3Y Avg | -16.2% |
| FCF/Rev LTM | -11.3% |
| FCF/Rev 3Y Avg | -20.5% |
Price Behavior
Price Behavior
| Market Price | $1.43 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/07/2011 | |
| Distance from 52W High | -92.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.46 | $5.85 |
| DMA Trend | down | down |
| Distance from DMA | -41.8% | -75.5% |
| 3M | 1YR | |
| Volatility | 106.1% | 93.1% |
| Downside Capture | 278.66 | 226.72 |
| Upside Capture | -170.92 | -130.78 |
| Correlation (SPY) | 24.8% | 10.1% |
VNRX Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.80 | 1.91 | 1.11 | 0.47 | 0.69 | 0.44 |
| Up Beta | 3.88 | 3.37 | 3.48 | 2.32 | 1.09 | 0.75 |
| Down Beta | 13.44 | 7.44 | 0.12 | -0.85 | 1.59 | 0.75 |
| Up Capture | -143% | -108% | -57% | -61% | -32% | -5% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 14 | 25 | 47 | 107 | 341 |
| Down Capture | -565% | 303% | 152% | 139% | 121% | 83% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 26 | 37 | 76 | 142 | 397 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VNRX | |
|---|---|---|---|---|
| VNRX | -89.1% | 100.3% | -1.75 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 5.9% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 10.8% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 3.8% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -1.0% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 7.7% |
| Bitcoin (BTCUSD) | -40.0% | 42.5% | -1.08 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VNRX | |
|---|---|---|---|---|
| VNRX | -54.2% | 88.8% | -0.49 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 11.4% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 13.8% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 6.1% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | 5.5% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 9.3% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | 13.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VNRX | |
|---|---|---|---|---|
| VNRX | -32.2% | 80.3% | -0.12 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 16.5% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 20.0% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 5.5% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 8.9% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 14.2% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | 9.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/18/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | -9.1% | 22.7% | -34.5% |
| 11/13/2025 | -6.6% | -5.9% | -31.7% |
| 8/14/2025 | 7.9% | 5.8% | -2.1% |
| 5/15/2025 | -5.2% | 14.0% | 57.6% |
| 11/14/2024 | -5.6% | 12.6% | -13.8% |
| 8/14/2024 | 3.2% | 23.1% | 23.0% |
| 5/13/2024 | -14.5% | -14.9% | -21.1% |
| 3/25/2024 | 4.1% | 7.6% | 11.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 14 | 10 |
| # Negative | 9 | 7 | 11 |
| Median Positive | 3.7% | 9.6% | 9.8% |
| Median Negative | -5.6% | -7.4% | -13.1% |
| Max Positive | 11.7% | 23.1% | 57.6% |
| Max Negative | -14.5% | -17.8% | -34.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/14/2026 | -9.1% | 22.7% | -34.5% |
| 11/13/2025 | -6.6% | -5.9% | -31.7% |
| 8/14/2025 | 7.9% | 5.8% | -2.1% |
| 5/15/2025 | -5.2% | 14.0% | 57.6% |
| 11/14/2024 | -5.6% | 12.6% | -13.8% |
| 8/14/2024 | 3.2% | 23.1% | 23.0% |
| 5/13/2024 | -14.5% | -14.9% | -21.1% |
| 3/25/2024 | 4.1% | 7.6% | 11.1% |
| 11/14/2023 | -1.3% | -12.7% | -11.4% |
| 8/14/2023 | -1.6% | 1.6% | 4.9% |
| 5/10/2023 | -1.0% | -17.8% | -18.3% |
| 3/15/2023 | 11.7% | 7.1% | 8.4% |
| 11/14/2022 | 6.0% | 19.3% | 21.7% |
| 8/10/2022 | 0.0% | -7.4% | -13.1% |
| 5/11/2022 | -9.8% | 11.5% | 1.7% |
| 11/10/2021 | 2.2% | 4.2% | -7.2% |
| 8/11/2021 | 0.6% | -2.8% | 0.6% |
| 5/11/2021 | 1.0% | 17.9% | 14.4% |
| 3/22/2021 | 11.2% | -0.9% | -5.2% |
| 11/12/2020 | 7.5% | 7.1% | 6.8% |
| 8/13/2020 | 3.3% | 5.7% | -4.5% |
| SUMMARY STATS | |||
| # Positive | 12 | 14 | 10 |
| # Negative | 9 | 7 | 11 |
| Median Positive | 3.7% | 9.6% | 9.8% |
| Median Negative | -5.6% | -7.4% | -13.1% |
| Max Positive | 11.7% | 23.1% | 57.6% |
| Max Negative | -14.5% | -17.8% | -34.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/15/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/31/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/25/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/15/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/11/2021 | 10-Q |
| 03/31/2021 | 05/11/2021 | 10-Q |
| 12/31/2020 | 03/22/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 02/20/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 08/12/2019 | 10-Q |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Barnes, Phillip | Direct | Buy | 4272025 | 1.30 | 5,000 | 6,500 | 32,092 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Barnes, Phillip | Direct | Buy | 4272025 | 1.30 | 5,000 | 6,500 | 32,092 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/20/2026